Blood markers may predict immunotherapy success in advanced cancers
NCT ID NCT03595813
First seen May 05, 2026 · Last updated May 22, 2026 · Updated 1 time
Summary
This study aimed to find blood-based markers that could predict how well patients with advanced lung cancer, lymphoma, or urologic cancers respond to immunotherapy. Researchers collected blood samples from 135 patients before and during treatment to track immune system changes. The goal was to understand why some patients benefit from these drugs while others do not.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institut Paoli-Calmettes
Marseille, Bouches-du-Rhône, France
Conditions
Explore the condition pages connected to this study.